Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUADRUPLE THREAT: RRx-001 in Platinum-Resistant Cancers
NCT02489903Phase 2Completed
- Sponsor
- EpicentRx
- Start
- Jun 2015
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Nibrozetone in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), Neuroendocrine Neoplasm (NEN), ovarian epithelial cancer, sponsored by EpicentRx. Started Jun 2015; status: completed.
02
Drugs
Nibrozetone
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)Neuroendocrine Neoplasm (NEN)ovarian epithelial cancer
Beyond the preview
Go deeper on NCT02489903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489903.